Medexus Pharmaceuticals Inc. (TSE:MDP – Free Report) – Investment analysts at Ventum Cap Mkts raised their Q1 2026 earnings per share estimates for Medexus Pharmaceuticals in a report issued on Wednesday, January 22nd. Ventum Cap Mkts analyst M. Czmielewski now anticipates that the company will post earnings of ($0.09) per share for the quarter, up from their prior estimate of ($0.10). Ventum Cap Mkts currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Ventum Cap Mkts also issued estimates for Medexus Pharmaceuticals’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.12) EPS.
Other equities research analysts also recently issued research reports about the company. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a report on Wednesday, January 8th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Stifel Nicolaus boosted their price objective on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Strong Buy” and a consensus price target of C$5.58.
Medexus Pharmaceuticals Stock Down 6.5 %
MDP stock opened at C$4.60 on Monday. The company has a market cap of C$112.84 million, a price-to-earnings ratio of 92.00 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The business has a 50 day moving average price of C$3.30 and a two-hundred day moving average price of C$2.74.
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Articles
- Five stocks we like better than Medexus Pharmaceuticals
- 3 Monster Growth Stocks to Buy Now
- Sizing Up a New Opportunity for NVIDIA Investors
- Best Aerospace Stocks Investing
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Quiet Period Expirations Explained
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.